Screening to detect Lynch syndrome and prevent hereditary cancers in relatives

Journal of Medical Screening

Volumn 18, Issue 4, 2011, Pages 167-168

  Haddow, James E ^a   Palomaki, Glenn E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G T MISMATCH BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

EDITORIAL; ENDOMETRIUM TUMOR; FEMALE; GENETIC SCREENING; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MALE; METHODOLOGY; MUTATION; UNITED STATES;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC TESTING; HUMANS; MALE; MUTATION; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; UNITED STATES;

EID: 84555191789     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2011.011139     Document Type: Editorial

References (12)

1. Recommendations from the EGAPP Working Group: genetic testing trategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41
2. Genomics. Healthy People 2020. U.S. Department of Health and Human Services. http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx? topicid=15 (last accessed October 21 2011)
3. Bonis PA, Trikalinos TA, Chung M, et al. Hereditary nonpolyposis olorectal cancer: accuracy of diagnostic strategies and implications to patients with colorectal cancer and their families. Evidence report/ echnology assessment No. 07-E008. Agency for Healthcare Research and Quality, Rockville, MD, 2007
4. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65
5. Jass JR. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol 2006;12:4943-50 (Pubitemid 44323261)
6. Johnson N, Barlow D, Lethaby A, Tavender E, Curr L, Garry R. Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials. BMJ 2005;330:1478
7. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-9 (Pubitemid 43113031)
8. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-34 (Pubitemid 30243745)
9. de Jong AE, Hendriks YM, Kleibeuker JH, et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 2006;130:665-71 (Pubitemid 43374516)
10. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011 [Epub ahead of print]
11. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on olorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50
12. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104